

# Presentations

Kaspar Rufibach, PhD  
Biostatistician  
<http://www.kasparrufibach.ch>

Last updated: 8th April 2025

---

## ORGANIZATION OF SEMINARS AND CONFERENCE SESSIONS:

- |            |   |
|------------|---|
| 17/06/2024 | PSI conference, Amsterdam, Netherlands. <i>Estimands for time-to-event outcomes: re-thinking old questions within the Estimand framework (organized with Evgeny Degtyarev).</i>   |
| 05/09/2023 | 5th Conference of the Central European Network, Basel, Switzerland. <i>Causal estimands for time to event data (organized with Vivian Lanius and Tobias Mütze).</i>   |
| 30/08/2023 | ISCB Milan, Italy. <i>Quantification of safety signals in clinical trials: Estimand, estimation, and how would good look like in ten years?.</i>  |
| 12/04/2023 | Seminar of the Basel Biometrics Society, Basel, Switzerland. <i>Quantification of risk: ask the right questions or time to apply the estimand framework to safety! (organized with Rema Izem).</i>  |
| 15/07/2022 | Seminar of the Basel Biometrics Society, Basel, Switzerland. <i>On market approval and market access: Breaking the linear thinking or how to innovate in a crowded space? (organized with Frank Bretz).</i>   |
| 21/09/2021 | ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop, Rockville, USA. <i>Clinical and Statistical Perspectives on Post-ICH E9 (R1) Addendum Estimand Use: Current Status and Future Directions (organized with Lei Nie and Shanti Gomataam, both FDA).</i>   |
| 07/09/2021 | Bi-annual conference of the Austrian-Swiss Region of the IBS, Salzburg, Austria. <i>How can statistics help to disrupt drug development? (organized with Marcel Wolbers).</i>   |
| 15/03/2021 | Bi-annual conference of the German Region of the IBS, Münster, Germany (virtual event). <i>Drug development beyond traditional paths: how can pharma and academia best collaborate to address today's drug development challenges? (organized with Cornelia-Ursula Kunz).</i> |
| 07/09/2020 | Seminar of the Basel Biometrics Society, Basel, Switzerland. <i>RCTs meeting causal inference: principal stratum strategy and beyond (organized with Björn Bornkamp and Giusi Moffa).</i>   |
| 06/09/2020 | Joint conference of the GMDS & CEN-IBS 2020, Berlin, Germany. <i>How can statistics help to disrupt drug development? (organized with Marcel Wolbers). Cancelled because of COVID-19 epidemic.</i>  |
| 06/09/2020 | Joint conference of the GMDS & CEN-IBS 2020, Berlin, Germany. <i>One year of ICH E9 addendum - examples of application and open problems (organized with Evgeny Degtyarev). Cancelled because of COVID-19 epidemic.</i>   |
| 06/09/2020 | Joint conference of the GMDS & CEN-IBS 2020, Berlin, Germany. <i>Causal inference methods in drug development after the ICH E9 addendum (organized with Giusi Moffa, Björn Bornkamp). Cancelled because of COVID-19 epidemic.</i>   |

- 29/06/2020 Joint seminar of the Basel Biometrics Society and EFSPI, Basel, Switzerland. *Estimands addendum is final: feeling the change? (organized with Evgeny Degtyarev, Bibiana Blatna, Marie-Laure Casadebaig, Lynda Grinstead, Lorenzo Guizzaro, Wolfgang Kothny, Giusi Moffa, Hans-Jochen Weber).*
- 01/11/2019 Seminar of the Basel Biometrics Society, Basel, Switzerland. *Predictive modelling, machine learning and causality (organized with Laurent Essioux, Dominik Heinzmann, Marcel Wolbers).*
- 31/07/2019 Joint Statistical Meetings, Denver, US. *Estimand Framework and Its Impact on Drug Development in Oncology (organized with Evgeny Degtyarev).*
- 10/05/2019 Spring seminar of the Basel Biometrics Society, Basel, Switzerland. *External controls - what do we need and how far can we go? (organized with Hans Ulrich Burger, Dominik Heinzmann, Simon Wandel).*
- 18/10/2018 Roche Early Development Research and Diagnostics Summit, Munich, Germany. *Statistical Know-How for Innovative Clinical Concepts (organized with Kerstin Trunzer).*
- 26/06/2018 Seminar of the Basel Biometrics Society, Basel, Switzerland. *RCTs, personalized medicine, and surrogacy (organized with Dietrich Knoerzer).*
- 20/03/2018 Seminar of the Basel Biometrics Society, Basel, Switzerland. *Competing Risks and Multistate Models (organized with Dietrich Knoerzer, Amanda Ross, Marc Vandemeulebroecke, Simon Wandel, Marcel Wolbers).*
- 13/09/2017 Roche European Biostatistics Conference, Welwyn, UK. *Network Meta Analysis - current challenges and the NICE perspective.*
- 23/08/2017 Conference of the Central European Network of the International Biometric Society, Vienna, Austria. *The assessment of probability of success for clinical trials (organized with Hans Ulrich Burger and Marcel Wolbers).*
- 18/06/2015 Joint Meeting of the International Biometric Society Austro-Swiss and Italian Regions, Milan, Italy. *Adaptive clinical trials with subpopulation selection (organized with Hans Ulrich Burger and Dominik Heinzmann).*

#### PODCASTS:

- 11/03/2025 The effective statistician podcast. *p-value and confidence intervals – the good, the bad, and the ugly.*
- 04/12/2024 The effective statistician podcast. *Introduction to dealing with non-proportional hazards.*
- 25/06/2024 The effective statistician podcast. *Managing hype in statistics.*
- 15/03/2024 Roche internal podcast for drug developers. *Futility analyses – a strategic tool in drug development that is not at all futile (jointly with Jenny Devenport, Gian Thanei, Marcel Wolbers, Uli Burger, Gaelle Klingelschmitt, Stefan Frings).*
- 11/07/2023 The effective statistician podcast. *Driving Statistical Innovation – Barriers And Strategies Part 2 (jointly with Mouna Akacha).*
- 04/07/2023 The effective statistician podcast. *Driving Statistical Innovation – Barriers And Strategies Part 1 (jointly with Mouna Akacha).*
- 01/12/2021 The effective statistician podcast. *200th episode - invited as one of contributors to the 10% most downloaded podcasts (jointly with Jan Beyersmann).*
- 06/07/2021 The effective statistician podcast. *SAVVY - a principled approach to the analysis of safety data (podcast jointly with Jan Beyersmann).*
- 30/04/2021 Roche R&D academy horizon magazine. *Put the question first! A plea for a principled approach to plan RWD studies (podcast jointly with Dominik Heinzmann).*

17/11/2020      The effective statistician podcast. *A deep dive into principal stratification and causal inference (podcast jointly with Björn Bornkamp).*

#### PANEL DISCUSSIONS:

07/11/2024      The effective statistician conference. *Beyond Delivering Tables and Reports - How Does Statistics Create Value Throughout R&D? Together with Nelson Kinnersley and Gary Sullivan.*

#### INVITED PRESENTATIONS:

20/03/2025      University of Zurich "Symposium of Causal Inference in the Health Sciences". *Estimands, Target Trial Emulation, and Use of External Control Data.*

19/03/2025      BBS seminar "From Statistical Innovations to Common Practice, How to innovate with impact?" (webinar). *Implementation of statistical innovation in a pharmaceutical company – it can be done!.*

23/01/2025      Statistical Methods Forum of the Mayo Clinic (webinar). *Estimands: a genuine step forward in designing, running, analyzing, and communicating clinical trials.*

19/11/2024      Joint PSI/EFSPi Causal Inference SIG Webinar: Opportunities in applying a causal inference framework during the analysis of an RCT. *Why clinical statisticians need to know about causal inference (webinar).*

11/09/2024      EFSPi regulatory statistics workshop, Basel, Switzerland. *CLL11 – a trial tailored to answer questions from many stakeholders efficiently.*

17/06/2024      PSI conference, Amsterdam, Netherlands. *Looking back on our oncology estimand SIG working group journey (talk together with Evgeny Degtyarev).*

23/05/2024      Annual meeting of the Danish Society for Biopharmaceutical Statistics. *Estimands, target trial emulation, and use of external control data.*

15/02/2024      Effective Statistician Academy. *Futility analyses - a strategic tool in drug development and not at all futile.*

23/11/2023      ACT EU Multi-Stakeholder Workshop on Methodology Guidance: A patient-centred approach to methodologies (Amsterdam, Netherlands). *EFSPi perspective on Complex Clinical Trials (talk together with Nicky Best).*

23/10/2023      Seminar of the Italian Biostatistics Group (IBIG, virtual). *Stop the abuse: A plea for a more principled approach to the analysis of time-to-event endpoints with varying follow-up times and/or competing risks, with a focus on analysis of AEs.*

12/10/2023      ASA/LUNGevity Foundation/FDA Statistical Forum (virtual). *Impact of Cross-over in the Evaluation of Overall Survival in Randomized Cancer Clinical Trials.*

30/08/2023      Annual Conference of the International Society for Clinical Biostatistics, Milan, Italy. *A plea for a more principled approach to the analysis of time-to-event endpoints with competing risks, with a focus on analysis of AEs.*

09/08/2023      Joint Statistical Meetings, Toronto, Canada. *Use of Bayesian Predictive Power in drug development: What to watch out for.*

21/06/2023      Seminar of the Basel Biometric Society, Basel, Switzerland. *Some hard truths about cross-industry collaborations and work-life balance.*

12/05/2023      Colloquium in honor of Lutz Dümbgen for his 60th birthday. *Assuming that PFS and OS are independent when designing a trial does not make sense.*

- 12/04/2023 Seminar of the Basel Biometric Society, Basel, Switzerland. *Stop the abuse: A plea for a more principled approach to the analysis of time-to-event endpoints with varying follow-up times and/or competing risks, with a focus on analysis of AEs.*
- 21/09/2022 Boehringer Ingelheim Data Science Department. *Bringing innovation to a large pharma company, exemplified using estimands and adaptive designs (virtual presentation).*
- 08/08/2022 Joint Statistical Meetings, Washington (US). *MIRROS: Planning a Phase 3 Trial with Time-to-Event Endpoint, a Cure Proportion, and a Futility Interim Analysis Using Response (virtual presentation).*
- 21/07/2022 UCB Statistical Methodology Group. *Bringing innovation to a large pharma company, exemplified using estimands and adaptive designs (virtual presentation).*
- 23/03/2022 Graham Dunn Seminar, Centre for Biostatistics at The University of Manchester. *ICH E9 estimands addendum: Old wine in new bottles or a genuine step forward? (webinar).*
- 16/12/2021 Section "Design methods for medical and clinical studies" of the Royal Statistical Society. *Answering Old Questions with New Tools: Application of the ICH E9 Addendum in Oncology (webinar).*
- 07/09/2021 Bi-annual conference of the Austrian-Swiss Region of the IBS, Salzburg, Austria. *MIRROS: Planning a Phase 3 Trial with Time-to-event Endpoint, a Cure Proportion, and a Futility Interim Analysis using Response.*
- 24/08/2021 China DIA estimands working group, China. *ICH E9 addendum and principal stratification (webinar).*
- 03/05/2021 Agência Nacional de Vigilância Sanitária /(ANVISA): Workshop on innovative and complex trials. *Two examples of innovative Phase 3 trials (webinar).*
- 29/04/2021 PSI One-Day Meeting: Non-proportional hazards and applications in immuno-oncology. *Planning a Phase 3 trial with time-to-event endpoint, a cure proportion, and a futility interim analysis using response (webinar).*
- 17/03/2021 DIA Europe 2021, Basel, Switzerland. *Stop the abuse: A plea for a more principled approach to the analysis of adverse events? (webinar).*
- 11/02/2021 ASA/LUNGEvity Foundation/FDA Statistical Forum (virtual): Statistical considerations in oncology clinical trials in the COVID-19 era. *How can the estimand framework support Decentralized Trials? (webinar).*
- 09/12/2020 Seminar, Vienna Biometric Section. *Use of multistate models to improve decision-making in clinical trials (webinar).*
- 27/11/2020 Meeting of the Working Group *Pharmaceutical Research* of the German Region of the IBS (webinar, talk together with Hannes Buchner). *Estimands update: Summary of world-wide authority interaction.*
- 21/10/2020 University of Basel, Basel. *Use of multistate models to improve decision-making in clinical trials (webinar).*
- 11/06/2020 PSI conference webinar. *Impact of COVID-19 to estimands (webinar).*
- 21/05/2020 Virtual panel discussion organized by Cytel. *Estimands in oncology.*
- 28/02/2020 University of Zurich / ETH applied statistics seminar, Zurich. *Use of multistate models to improve decision-making in clinical trials.*
- 25/02/2020 Joint workshop Swissmedic / swissethics "Workshop Complex Clinical Trials", Bern. *A statistician's view on complex innovative designs.*
- 14/11/2019 MRC Biostatistics Unit, Cambridge, UK. *Use of multistate models to jointly model progression-free and overall survival and improve decision-making in clinical trials.*
- 16/10/2019 Clinical Trials Europe, Basel, Switzerland. *Implications of the ICH E9 estimand addendum on how we develop, run, and analyze clinical trials.*

- 10/09/2019 Conference of the Austro-Swiss Region of the IBS, Lausanne, Switzerland. *Before going BIG - seize opportunities for small data: use of multistate models to improve decision-making and effect quantification in clinical trials.*
- 04/07/2019 PSI webinar. *rpact - R Package for Adaptive Clinical Trials.*
- 27/06/2019 Shanghai Biostatistics Forum, Shanghai, China. *Multistate models to improve decision-making and effect quantification in clinical trials.*
- 23/05/2019 Bayesian Biostatistics Conference (bayes-pharma), Lyon, France. *Bayesian Predictive Power: Theory, challenges in implementation, and perspectives.*
- 10/05/2019 Spring seminar of the Basel Biometric Society, Basel, Switzerland. *External controls in drug development (with Hans Ulrich Burger).*
- 02/04/2019 SMi conference on adaptive clinical trials, London, UK. *MIRROS: Phase 3 trial with time-to-event endpoint, cure proportion, and futility interim analysis using response.*
- 22/11/2018 Statistics seminar, University of Bochum, Germany. *Univariate log-concave density estimation and more efficient treatment effect estimation in pre-specified subgroups displayed in forest plots for time-to-event outcomes.*
- 23/10/2018 Oncology workshop, University of Heidelberg, Germany. *MIRROS: Planning a Phase 3 trial with time-to-event endpoint, a cure proportion, and a futility interim analysis using response.*
- 18/10/2018 Roche RxDx summit, Munich, Germany. *Randomization and External Controls - When to Use What in a Drug Development Landscape.*
- 10/09/2018 Modeling and Simulation seminar, Basel, Switzerland. *Immortal bias - you live longer if you cannot die.*
- 21/06/2018 Biostatistics group Boehringer-Ingelheim, Biberach, Germany. *Overall survival prediction conditional on post-randomization events: multistate models, landmark analyses, and others.*
- 13/02/2018 Special Colloquia Epidemiology, Biostatistics, and Prevention Institute, University of Zurich, Zurich, Switzerland. *Estimands and the ICH E9 draft addendum.*
- 24/11/2017 Meeting of the Working Group *Pharmaceutical Research* of the German Region of the IBS, Freiburg, Germany. *Treatment effect measures for time-to-event endpoints - estimands, analysis strategies, and beyond.*
- 03/11/2017 Adaptive Clinical Trials Summit, Berlin, Germany (conference was cancelled). *MIRROS - a phase III trial with overall survival primary endpoint, a cure proportion, and a futility interim analysis using response and event-free survival.*
- 04/10/2017 2nd EFSPi Regulatory Statistics Workshop, Basel, Switzerland. *Construction of an Estimand in a Clinical Trial on Progressive Multiple Sclerosis.*
- 31/08/2017 Joint Meeting of the International Biometric Society Austro-Swiss, German, and Polish Region, Vienna, Austria. *Evolution of assurance over the lifecycle of several Phase 3 trials in a large oncology clinical development program.*
- 13/06/2017 Workshop on Innovation in Oncology Clinical Trial Design, organized by the Cancer Drug Development Forum (CDDF), Frankfurt. *Treatment effect measures for time-to-event endpoints - Estimands and beyond.*
- 13/03/2017 Seminar, Basel Biometric Society, Basel. *Comparison of clinical development plans for a confirmatory trial with subpopulation selection.*
- 12/12/2016 Statistics Seminar, Institute for Medical Biometry, University of Heidelberg, Heidelberg. *Bayesian Predictive Power: update after a blinded interim analysis and choice of update after a blinded interim analysis and choice of prior.*
- 14/11/2016 European Statistical Forum, Berlin. *Estimands for time to event endpoints.*
- 10/11/2016 Statistics Seminar, Institute for Social and Preventive Medicine, University of Lausanne, Lausanne. *Bayesian Predictive Power: update after a blinded interim analysis and choice of prior.*

- 12/09/2016 1st EFSPI Regulatory Statistics Workshop, Basel. *Estimands for time to event endpoints in oncology and beyond (delivered by Uli Burger)*.
- 24/05/2016 PSI conference, Berlin. *Time to think about estimands for time-to-event endpoints? A few examples (delivered by Uli Burger)*.
- 28/04/2016 Seminar, Basel Biometric Society, Basel. *Event projection: quantify uncertainty and manage expectations of broader teams*.
- 02/03/2016 Statistics Seminar, University of Ulm, Ulm. *Bayesian Predictive Power: Choice of Prior and some Recommendations for its Use as Probability of Success in Drug Development*.
- 20/11/2015 3rd BIMIT (Verbundprojekt “Biostatistische Methoden zur effizienten Evaluation von Individualisierten Therapien”) workshop, Göttingen. *A Weibull Regression Model for a Time-to-Event Endpoint with an Interval-Censored Covariate and its Application in Assessing Prentice’s Criteria for Surrogacy*.
- 27/10/2015 Seminar, Basel Biometric Society, Basel. *Bayesian Predictive power: the bathtub phenomenon*.
- 18/06/2015 Joint Meeting of the International Biometric Society Austro-Swiss and Italian Regions, Milan, Italy. *Comparison of clinical development plans for a confirmatory trial with subpopulation selection*.
- 17/04/2015 Seminar, Institute for Mathematical Statistics and Actuarial Science, University of Bern, Switzerland. *Bayesian predictive power: update after a blinded interim & fallacies*.
- 20/11/2014 2nd BIMIT (Verbundprojekt “Biostatistische Methoden zur effizienten Evaluation von Individualisierten Therapien”) workshop, Bremen. *How good is your biomarker? Comparison of development plans for confirmatory biomarker enrichment*.
- 11/11/2014 Joint DIA/AEMPS Statistics Workshop, Barcelona. *How good is your biomarker? Comparison of development plans for confirmatory biomarker enrichment*.
- 18/09/2014 2nd Symposium for the RxDx Generation, Roche, Penzberg. *How statistics can contribute to innovative trials*.
- 27/03/2014 University of Zurich / ETH applied statistics seminar, Zurich. *Update Bayesian predictive power after a blinded interim analysis*.
- 12/05/2010 Research Section Meeting Royal Statistical Society, London. *Proposal of the vote of thanks in discussion of Cule, M., Samworth, R., and Stewart, M.: Maximum likelihood estimation of a multidimensional logconcave density*.
- 26/01/2010 Workshop “Statistical Issues in Prediction: What can be Learned for Individualized Predictive Medicine?”, Oberwolfach, Germany. *Score regression: a new approach to assess calibration of continuous probabilistic predictions*.
- 12/01/2010 Seminar, Basel Biometric Society, Basel. *Ordered monotone regression*.
- 11/02/2009 Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, CA, USA. *Regularized regression models in R*.
- 17/01/2008 Seminar, Basel Biometric Society, Basel. *A general criterion for multiscale inference*.
- 18/12/2007 Seminar, Institute for Stochastics, University of Karlsruhe, Germany. *Nonparametric Estimation of Log-Concave Densities*.
- 28/09/2007 Seminar, Institute for Mathematical Statistics and Actuarial Science, University of Bern, Switzerland. *A general criterion for multiscale inference*.
- 13/09/2007 Basel Institute for Clinical Epidemiology, University of Basel, Switzerland. *Predicting Alzheimer from proteomic blood markers*.
- 31/07/2007 Seminar, Statistics Department, Stanford University, United States. *Max-domain of attraction for log-concave densities and smooth tail index estimation*.

- 11/11/2006 Workshop “Qualitative Assumptions and Regularization in High-Dimensional Statistics”, Oberwolfach, Germany. *The log-concave density estimator as a smoother.*
- 23/08/2005 Seminar, Statistics Department, Stanford University, United States. *Log-concave density estimation.*

#### CONTRIBUTED CONFERENCE PRESENTATIONS:

- 19/06/2024 PSI conference, Amsterdam, Netherlands. *Implementation of statistical innovation in a pharmaceutical company.*
- 05/09/2023 Conference of the Central European Network of the International Biometric Society (CEN 2023), Basel, Switzerland. *Oncology clinical trial design based on a multistate model that jointly models progression-free and overall survival.*
- 28/08/2022 Annual Conference of the International Society for Clinical Biostatistics, Milan, Italy. *Oncology clinical trial design based on a multistate model that jointly models progression-free and overall survival.*
- 22/08/2022 Annual Conference of the International Society for Clinical Biostatistics, Newcastle, UK. *Follow-up time in clinical trials with a time-to-event endpoint: Redefining the question(s).*
- 04/06/2019 PSI annual conference, London, UK. *Estimand framework in Oncology drug development – impact and opportunities.*
- 19/03/2019 Annual Meeting of the International Biometric Society, German Region, Munich, Germany. *Estimand framework in Oncology drug development – impact and opportunities (talk delivered by Björn Bornkamp).*
- 17/10/2018 Roche Global Biostatistics Conference, Madrid, Spain. *Assess Common Surrogate Endpoints in Lymphoma using a Multistate Model.*
- 04/10/2018 Workshop on Adaptive Designs and Multiple Testing Procedures, Bremen, Germany. *More efficient treatment effect estimation in pre-specified subgroups displayed in forest plots for time-to-event outcomes.*
- 28/03/2018 Annual Meeting of the International Biometric Society, German Region, Frankfurt, Germany. *The Estimand Framework Applied to Time-to-event Endpoints.*
- 12/07/2017 Annual Conference of the International Society for Clinical Biostatistics, Vigo, Spain. *Joint modelling of progression-free and overall survival.*
- 23/08/2016 Annual Conference of the International Society for Clinical Biostatistics, Birmingham, Great Britain. *Bayesian Predictive Power: Choice of Prior and some implications.*
- 24/05/2016 PSI annual conference, Berlin, Germany. *Bayesian Predictive Power: Choice of Prior and some Recommendations for its Use as Probability of Success in Drug Development (delivered by Markus Abt).*
- 16/06/2015 Joint Meeting of the International Biometric Society Austro-Swiss and Italian Regions, Milan, Italy. *Evaluation of possible designs for a three-arm clinical trial: Comparing a closed-testing design to potential alternatives.*
- 20/05/2015 Roche Global Biostatistics Conference, San Francisco, United States. *Evaluation of possible designs for a three-arm clinical trial: Comparing the CLL11 design to potential alternative designs.*
- 28/08/2014 Annual Conference of the International Society for Clinical Biostatistics, Vienna, Austria. *Weibull Regression for a Right-Censored Endpoint with a Censored Covariate.*
- 02/07/2014 Bayesian Biostatistics 2014 - Satellite conference of the International Biometric Conference, Zurich, Switzerland. *Update Bayesian predictive power after a blinded interim analysis.*
- 23/10/2013 Update Bayesian Predictive Power after a blinded interim analysis, Roche Global Biostatistics Conference, Brighton, United Kingdom.

13/09/2011	Conference of the Central European Network of the International Biometric Society (CEN 2011), Zurich, Switzerland. <i>A smooth ROC curve estimator based on log-concave density estimates.</i>
21/06/2011	Methods in Meta Analysis Meeting, London, UK. <i>Selection models with monotone weight functions in meta analysis.</i>
03/08/2010	Joint Statistical Meetings, Vancouver, Canada. <i>Ordered Monotone Regression.</i>
02/03/2010	German Open Conference on Probability and Stochastics, Leipzig, Germany. <i>Ordered Monotone Regression.</i>
12/03/2008	Conference of the Central European Network of the International Biometric Society (Lifestat 2008), Munich, Germany. <i>On a new approach to regression models with ordinal explanatory variables.</i>
11/09/2007	ROeS Seminar 2007, Bern, Switzerland. <i>On a new approach to regression with ordered explanatory variables.</i>
15/03/2006	German Open Conference on Probability and Stochastics, Frankfurt, Germany. <i>Smoothed semi-parametric tail index estimation and max-domain of attraction for log-concave densities.</i>
27/07/2005	European Meetings of Statisticians, Oslo, Norway. <i>Log-concave density estimation.</i>
19/07/2005	European Young Statisticians Training Camp, Oslo, Norway. <i>Log-concave density estimation and bump hunting.</i>
26/03/2004	German Open Conference on Probability and Stochastics, Karlsruhe, Germany. <i>Log-concave density estimation and uniform rate of convergence.</i>
06/08/2003	Joint Statistical Meetings, San Francisco, United States. <i>Computing maximum likelihood estimators of log-concave densities.</i>

#### INTERNAL METHODOLOGICAL PRESENTATIONS:

03/03/2025	How to accelerate drug development and some comments on adaptive designs (Merck Biostatistics Forum).
29/01/2025	I do not care what FDA says! (Merck Patient Real World Evidence offsite meeting).
05/11/2024	Futility analysis – not at all futile (Merck Biostatistics Forum).
17/06/2024	Anyone who has visions should go to the doctor! My vision how statistician will remain relevant in the future (Roche Basel / Welwyn Biostatistics Community Forum).
25/04/2024	Statistical innovation in pharmaceutical industry - key to drug development success (Roche global biostatistics conference, Montreal).
13/03/2023	Assuming that PFS and OS are independent when designing a trial does not make sense! (Roche Basel / Welwyn Biostatistics Community Forum).
09/03/2023	Assuming that PFS and OS are independent when designing a trial does not make sense! (Roche North America Biostatistics Community Forum).
24/01/2023	Platform trials: demystifying the statistics (Roche Basel / Welwyn oncology forum).
18/01/2023	Drug Safety's View on Data & Data Analysis (jointly with Rajat Mohindra, Marianne Gerber, Christian Müller, Carina Hillenbach, North America Data sciences group at Roche).
12/09/2022	Optimising the use of Real-World Data and Real-World Evidence across Europe (Basel / Welwyn Biostatistics Community Forum at Roche).
15/08/2022	Follow-up time in clinical trials with a time-to-event endpoint: Redefining the question(s) (Basel / Welwyn Biostatistics Community Forum at Roche).



10/08/2022	Bringing innovation to a large pharma company, exemplified using estimands and adaptive designs (Industry Collaborations Thought Leaders Group at Roche).
25/07/2022	Drug Safety's View on Data & Data Analysis (jointly with Rajat Mohindra, Marianne Gerber, Christian Müller, Carina Hillenbach, Europe & Asia Data sciences group at Roche).
19/01/2022	Stop the abuse: A plea for a more principled approach to the analysis of time-to-event endpoints with competing risks, with a focus on analysis of AEs (presented to safety analytics group at Roche).
01/09/2021	Platform trials: demystifying the statistics (presented to all scientists across Roche).
15/06/2020	Complex innovative designs: adaptive, basket, umbrella and beyond (presented to all Roche statisticians globally in virtual seminars).
13/08/2019	External controls in drug development (Roche Oncology Forum, Basel & Welwyn).
27/06/2019	MIRROS: Planning a Phase 3 trial with time-to-event endpoint, a cure proportion, and a futility interim analysis using response (Roche Biostatistics Department, Shanghai).
18/03/2019	To explain or to predict - what is the difference? And how to plan a prediction model? (Biostatistics workshop, Department of Biostatistics, Basel).
27/02/2019	To be fast or to be sure? Trade-offs in drug development (Roche Early Development and Research (pRED) Science@Site Lecture Series, Basel).
30/01/2019	MIRROS: Planning a Phase 3 trial with time-to-event endpoint, a cure proportion, and a futility interim analysis using response (Roche Biostatistics Department, Welwyn).
16/07/2018	Extract more information from a clinical trial than just Kaplan-Meier estimates of the primary endpoint: a case study in multistate modeling (Biostatistics workshop, Department of Biostatistics, Basel).
09/10/2017	Quantification of follow-up for a time-to-event endpoint (Biostatistics workshop, Department of Biostatistics, Basel).
20/09/2017	Joint modelling of progression-free and overall survival (Seminar, Roche Germany Biostatistics and Epidemiology Group, Grenzach).
13/09/2017	Estimands - a refinement of ITT (jointly with Chris Harbron, Roche Basel - Welwyn - Shanghai Biostatistics Conference, Welwyn).
23/05/2017	Estimands – current ICH E9 working group proposal (jointly with Chris Harbron, Genentech North America Biostatistics Seminar, South San Francisco).
19/12/2016	Estimands – do you know what you are estimating? (Roche HTA group, Basel).
24/11/2016	Compare Phase 3 with futility interim to randomized Phase 2 + Phase 3 and single-arm Phase 2 + Phase 3 (Roche Statistics Workshop, Welwyn).
25/09/2016	Immortal time bias and post-randomization variables (jointly with Marcel Wolbers, Roche Statistics Workshop, Basel).
11/05/2016	Bayesian Predictive Power - Choice of Prior (Genentech North-American Biostatistics Forum, South San Francisco).
15/10/2015	Estimands – do you know what you are estimating? (Roche Basel & Welwyn Joint Biostatistics Seminar, Welwyn).
29/09/2015	Hierarchical testing of a secondary endpoint in a group-sequential design (Roche Statistics Workshop, Welwyn).
17/08/2015	Bayesian Predictive power: the bathtub phenomenon (Roche Statistics Workshop, Basel).

16/02/2015	Hierarchical testing of a secondary endpoint in a group-sequential design (Roche Statistics Workshop, Basel).
20/08/2014	Estimation of a survival curve beyond where we have data, with application to event tracking for time-to-event outcomes (Health Economics Department, Roche Basel).
11/08/2014	Event tracking for time-to-event outcomes (Roche Asia Pacific Biostatistics Workshop).
24/07/2014	Statistical MythBusters (Roche Oncology Forum, Basel & Welwyn).
16/06/2014	Event tracking for time-to-event outcomes (Roche Statistics Workshop, Basel).
17/12/2013	Immortal bias - or why it is a bad idea to plot a time-to-event endpoint by response category (Roche Statistics & Oncology Forum, Shanghai).
06/11/2013	Some examples for R and Sweave applications (Roche Statistical Programming Workshop, Basel).
02/09/2013	Immortal bias - or why it is a bad idea to plot a time-to-event endpoint by response category (Roche Biostatistics Basel/Welwyn/Shanghai Meeting, Basel).
04/02/2013	Probability of technical success: Conditional Power, Bayesian Predictive Power, or Bayesian Updating? (Roche Biostatistics Basel/Welwyn/Shanghai Meeting, Basel).
17/12/2012	Writing R packages and use of Sweave (Roche Statistics Workshop, Basel).
30/11/2012	Probability of technical success - two ways of looking at it (Roche pRED Meeting, Basel/Nutley).
19/11/2012	Unbiased estimation of a proportion after a 2-stage trial (Roche Statistics Workshop, Basel).
12/07/2012	A new smooth ROC curve estimate based on log-concave densities (Roche Biostat Biomarker Community Meeting, Basel).
27/01/2011	Categorization of continuous covariates (Zurich).
03/12/2009	$p$ -values in high-dimensional regression (Zurich).
04/06/2009	Estimation and computation of the median for right-censored data (Zurich).
12/01/2009	Consulting and reproducible research (Zurich).
06/11/2008	Exact logistic regression (Zurich).
06/03/2008	$L_1$ and Least angle regression (Zurich).
06/12/2007	On a new approach to regression with ordinary explanatory variables (Zurich).
25/01/2006	Semi-parametric tail index estimation and max-domain of attraction for log-concave densities (Bern).
04/05/2005	Local asymptotic normality and Le Cam's third lemma (Bern).
11/01/2005	Penalized estimators (Bern).
01/12/2004	Asymptotics for Lasso-Type Estimators (Bern).
28/04/2004	Estimation of a Proportion in Group Sequential Trials (Bern).
26/11/2003	Density Estimation under Qualitative Assumptions (Bern).
07/01/2003	Convex Programming (Bern).